Hcw Biologics INC 8-K filings

HCW Biologics Inc. reported the full exercise of all outstanding pre-funded warrants by Armistice Capital Master Fund Ltd., completing a previously announced securities purchase agreement.

HCW Biologics Inc. announced it has regained full compliance with all Nasdaq Capital Market listing requirements, resolving previous delisting concerns.

HCW Biologics Inc. successfully held its 2025 Annual Meeting of Stockholders despite technical difficulties, electing directors and ratifying auditors, while also accepting a board member's resignation.

HCW Biologics Inc. announced that Armistice Capital Master Fund Ltd. has continued to exercise pre-funded warrants, acquiring an additional 85,000 shares of common stock on June 12, 2025, with 54,000 shares remaining under warrant.

HCW Biologics Inc. announced it has regained full compliance with Nasdaq listing requirements, secured a $7.0 million upfront payment from a licensing agreement with WY Biotech, and closed a $5.0 million equity offering.

HCW Biologics Inc. announced that WY Biotech Co., Ltd. has completed its due diligence and committed to the exclusive worldwide license agreement for HCW11-006, triggering a $7.0 million upfront licensing fee.

HCW Biologics Inc. announced the latest exercise of pre-funded warrants by Armistice Capital, resulting in the issuance of 71,000 common shares and leaving 139,000 warrants outstanding.

HCW Biologics Inc. announced the issuance of 126,000 common shares to Armistice Capital Master Fund Ltd. on May 22, 2025, following the exercise of pre-funded warrants, with 210,000 warrants remaining.

HCW Biologics Inc. announces the issuance of common stock to Armistice Capital and the conversion of convertible bridge notes into common stock for company executives and board members.

HCW Biologics announces its Q1 2025 financial results, business highlights, and the closing of a $5 million equity offering.

HCW Biologics announces a $5.0 million follow-on offering of units priced at-the-market, consisting of common stock (or pre-funded warrants) and warrants.

HCW Biologics is facing a lawsuit from BE&K Building Group and potential loan default due to unpaid invoices related to the construction of its new headquarters and GMP manufacturing facilities.

HCW Biologics submitted a registration statement for the resale of common stock by certain investors, including shares issuable under an equity line and a purchase warrant.

HCW Biologics has enacted a 1-for-40 reverse stock split, effective April 11, 2025, to meet Nasdaq's minimum bid price requirement.

HCW Biologics Inc. announces stockholder approval of a reverse stock split, an equity line of credit, and a note conversion proposal at a Special Meeting held on March 31, 2025.

HCW Biologics announced its fourth quarter and fiscal year 2024 financial results, highlighting business development transactions and clinical development progress.

HCW Biologics and WY Biotech amend their agreement, restructuring payment schedules and milestones due to a delay in WY Biotech securing a CDMO.

HCW Biologics receives an extension from Nasdaq to meet continued listing requirements, with deadlines set for April 25, 2025, and June 15, 2025.

HCW Biologics enters into an agreement with Square Gate Capital for the potential sale of up to $20 million in common stock over the next 36 months.

HCW Biologics Inc. is at risk of being delisted from the Nasdaq Stock Market after failing to regain compliance with the minimum bid price and market value requirements.

HCW Biologics has been cleared by the FDA to begin a Phase 1 clinical trial for HCW9302, a potential treatment for moderate to severe alopecia areata.

HCW Biologics has received a delisting notice from Nasdaq after failing to maintain the required market value of listed securities, and plans to appeal the decision.

HCW Biologics issued 2,557,000 shares of common stock to Armistice Capital after the exercise of pre-funded warrants.

HCW Biologics has raised approximately $6.9 million through a registered direct offering and concurrent private placement, while also licensing a preclinical immunotherapeutic candidate to WY Biotech for a $7 million upfront payment.

HCW Biologics has entered into an exclusive worldwide licensing agreement with WY Biotech for a preclinical molecule, securing an upfront payment of $7 million and potential future royalties.

HCW Biologics announced its third quarter 2024 financial results, highlighting progress in its immunotherapy programs and a new financing plan.

HCW Biologics has dismissed Grant Thornton as its auditor and appointed Crowe LLP, following a restatement of financials due to a fraud incident and concerns about the company's ability to continue as a going concern.

HCW Biologics issued a corrected press release for its second quarter 2024 financial results, addressing a clerical error in the previously reported cash balance and highlighting a settlement agreement and new financing initiatives.

HCW Biologics announced its second quarter 2024 financial results, highlighting a settlement agreement, new financing plans, and ongoing development of its immunotherapies.

HCW Biologics has received notices from Nasdaq for failing to maintain a minimum bid price of $1 per share and a market value of publicly held securities above $15 million, putting its listing at risk.